[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kissei Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,60,82],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100639605",false,"NCT07604064","A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia","A Phase II Clinical Trial of Olutasidenib in Patients With Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Japanese patients who personally provide written informed consent to participate in this clinical trial\n* Patients with a confirmed diagnosis of AML based on WHO classification (2022 edition) (except acute promyelocytic leukemia with t (15:17) translocation)\n* Patients with relapsed or refractory AML who may or may not have undergone allogeneic hematopoietic stem cell transplantation.\n* Patients with IDH1 gene mutation confirmed by central confirmation after relapse or refractoriness\n\nExclusion Criteria:\n\n* Patients with IDH2 mutations or patients with a history of IDH2 inhibitor treatment\n* Patients who are intolerant to IDH1 inhibitors\n* Patients who are deemed inappropriate for the clinical trial by the investigator or sub-investigator","ALL","18 Years",{"count":18,"type":19},3,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.",[25],"Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia","RECRUITING","2026-05-22",{"date":29,"type":30},"2026-05-27","ACTUAL",{"date":32,"type":19},"2026-06",{"date":34,"type":19},"2030-09",{"name":36,"class":37},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":38},"100596029","NCT07040137","Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration","Inclusion Criteria:\n\n* Japanese SCD patients with mild to moderate ataxia\n\nExclusion Criteria:\n\n* Patients with secondary ataxia\n* Patients with clinically significant hepatic, renal, or cardiovascular dysfunction",{"count":46,"type":19},142,[48],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.",[51],"Spinocerebellar Degeneration","2025-06-25",{"date":54,"type":30},"2025-06-27",{"date":56,"type":19},"2025-07",{"date":58,"type":19},"2027-03-31",{"name":36,"class":37},{"id":61,"slug":4,"hasResults":10,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":66,"targetDuration":68,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":38},"100574360","NCT06758271","Special Drug Use-results Survey for Long-term Use（Avacopan）","Special Drug Use-results Survey for Long-term Use","Inclusion Criteria:\n\n* Patients with granulomatosis with polyangiitis or microscopic polyangiitis who are treatment with avacopan",{"count":67,"type":19},250,"2 Years","OBSERVATIONAL","The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.",[72,73],"Microscopic Polyangiitis (MPA)","Granulomatosis With Polyangiitis (GPA)","2025-01-15",{"date":76,"type":30},"2025-01-17",{"date":78,"type":30},"2022-07-29",{"date":80,"type":19},"2028-05-31",{"name":36,"class":37},{"id":83,"slug":4,"hasResults":10,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":69,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":38},"100574282","NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.",{"count":88,"type":19},149,"18 Months","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.",[92],"Chronic Idiopathic Thrombocytopenic Purpura","2024-12-26",{"date":95,"type":30},"2025-01-03",{"date":97,"type":30},"2023-05-29",{"date":99,"type":19},"2028-09-30",{"name":36,"class":37},""]